Valuation: Simulations Plus, Inc.

Market Cap 371M 322M 301M 276M 521M 35.33B 527M 3.53B 1.38B 17.65B 1.39B 1.36B 58.76B P/E 2026 *
43.7x
P/E 2027 * 40.1x
Enterprise Value 371M 322M 301M 276M 521M 35.33B 527M 3.53B 1.38B 17.65B 1.39B 1.36B 58.76B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.3x
Free-Float
83.09%
Yield 2026 *
-
Yield 2027 * -
1 day+0.11%
1 week+0.05%
Current month+0.60%
1 month-0.27%
3 months+16.74%
6 months+29.70%
Current year+0.60%
1 week 18.22
Extreme 18.22
18.36
1 month 18.19
Extreme 18.19
18.42
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.9
Extreme 7.9
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Executive/Senior Manager

-1,000 0.0050%
6/7/26 Sell

Executive/Senior Manager

-1,000 0.0050%
1/7/26 Sell

Founder

-4,177 0.0207%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%+0.05%+42.06%-63.75% 371M
+2.01%+4.76%-22.62%+10.60% 34.68B
+0.19%+10.71%-44.35%+150.47% 13.28B
-1.19%-6.57%-25.08%+62.73% 5.44B
+0.07%+8.59% - - 2.34B
-4.14%+6.19% - - 1.86B
-2.72%-12.66%+18.56%-44.35% 1.69B
-2.36%+0.23%-36.83% - 1.04B
-1.73%+5.83%+33.14%+112.15% 913M
-0.27%+8.55%-38.26%-48.96% 847M
Average -1.07%+2.96%-9.17%+25.56% 6.25B
Weighted average by Cap. +0.48%+3.68%-25.80%+46.64%

Financials

2026 *2027 *
Net sales 81.87M 71.05M 66.53M 60.86M 115M 7.8B 116M 778M 305M 3.9B 307M 301M 12.97B 86.26M 74.85M 70.09M 64.12M 121M 8.22B 123M 820M 322M 4.11B 324M 317M 13.66B
Net income 9.53M 8.27M 7.75M 7.09M 13.38M 908M 13.55M 90.63M 35.57M 454M 35.8M 35.02M 1.51B 10.18M 8.84M 8.27M 7.57M 14.29M 970M 14.47M 96.79M 37.98M 485M 38.23M 37.4M 1.61B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
06/08/26 USD 18.34 +0.11% 137,064
05/08/26 USD 18.32 -0.16% 160,523
04/08/26 USD 18.35 +0.22% 150,057
03/08/26 USD 18.31 +0.44% 208,917
31/07/26 USD 18.23 -0.38% 377,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.34USD
Average target price
17.25USD
Spread / Average Target
-5.94%

Quarterly revenue - Rate of surprise